Charge variants of proposed biosimilar to Omalizumab: Isolation, purification and analysis by HPLC methods
Annales Pharmaceutiques Françaises · 2024
DOI: 10.1016/j.pharma.2023.09.003 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annales Pharmaceutiques Françaises, 2024. Verfasst von Tarun Gupta und 1 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Science, Nirma University, 382481 Ahmedabad, Gujarat, India; Downstream Process Development, Kashiv BioSciences Pvt Ltd., 382210 Ahmedab…. Hauptthemen laut MEDLINE: Omalizumab, Biosimilar Pharmaceuticals. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 20 Literaturangaben. Gefördert von: Nirma University.
Abstract (Originalsprache)
Omalizumab (Xolair) is a humanized monoclonal antibody derived by recombinant DNA technology. It binds specifically to immunoglobulin E (IgE) which plays a major role in allergic reaction by releasing histamine and other inflammatory factors from mast cells. Omalizumab binds circulatory IgE with high affinity and prevents from its binding to mast cell receptor. Charge variants are one of the critical quality attributes (CQAs) in biological drug development and sources of heterogeneity which needs to be considered in biosimilarity assessment. In this study, biosimilar product of Xolair was expressed in mammalian cell culture process in laboratory to isolate charge variants (acidic, main peak and basic). Different charge variants were isolated from intermediate purified biosimilar product of Xolair. Isolated charge variants were purified with preparative cation exchange chromatography technique and characterized with different analytical tools includes size exclusion chromatography (SEC-HPLC) and cation exchange chromatography (CEX-HPLC). Purity of acidic, main peak and basic variants was 99.58%, 99.98% and 98.64% respectively as per SEC-HPLC and according to CEX-HPLC purity was 94.25%, 95.58% and 91.33% respectively. The study data indicates that isolated charge variants were purified with desired purity and can be further used for process characterization, in vitro potency and in vivo kinetics studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Science, Nirma University, 382481 Ahmedabad, Gujarat, India; Downstream Process Development, Kashiv BioSciences Pvt Ltd., 382210 Ahmedabad, Gujarat, India.
- Institute of Science, Nirma University, 382481 Ahmedabad, Gujarat, India. Electronic address: sriram.seshadri@nirmauni.ac.in.
Förderung
- Nirma University
Zitieren
APA
Gupta, T., & Seshadri, S. (2024). Charge variants of proposed biosimilar to Omalizumab: Isolation, purification and analysis by HPLC methods. Annales Pharmaceutiques Françaises. https://doi.org/10.1016/j.pharma.2023.09.003
Vancouver
Gupta T, Seshadri S. Charge variants of proposed biosimilar to Omalizumab: Isolation, purification and analysis by HPLC methods. Annales Pharmaceutiques Françaises. 2024. doi:10.1016/j.pharma.2023.09.003
BibTeX
@article{Gupta2024,
author = {Gupta, Tarun and Seshadri, Sriram},
title = {Charge variants of proposed biosimilar to Omalizumab: Isolation, purification and analysis by HPLC methods},
journal = {Annales Pharmaceutiques Françaises},
year = {2024},
doi = {10.1016/j.pharma.2023.09.003}
}
EUVIMED